Uzun Öznur, Özcan Didem Sezgi N, Arslan Hilal Buse, Bilir Emine Esra, Şentürk Başak, Tezen Özge
Ankara Bilkent City Hospital, Ankara, Turkey.
Medicana International Ankara Hospital, Ankara, Turkey.
Lasers Med Sci. 2025 May 19;40(1):231. doi: 10.1007/s10103-025-04492-x.
TECAR therapy is a thermotherapy modality that enhances microcirculation, reduces inflammation, and supports tissue regeneration by generating heat in superficial and deep tissues. This study aimed to evaluate the effects of TECAR therapy on pain and functional outcomes in patients with adhesive capsulitis (AC). This prospective, randomized, single-blind, controlled clinical trial included 60 patients [TECAR group: 30, (50.37 ± 13.90 years); control group: 30, (55.27 ± 10.44 years)]. Both groups completed a 2-week tailored therapeutic exercise program, with 30-min hot pack application and Transcutaneous Electrical Nerve Stimulation. The TECAR group also received three TECAR therapy sessions per week, for a total of six sessions. Pain was measured using the Visual Analog Scale (VAS), functional status with the Shoulder Pain and Disability Index (SPADI), and supraspinatus tendon thickness and bicipital effusion were assessed via ultrasonography. Evaluations were conducted at baseline, 1 and 3 months post-treatment. Both groups showed significant reductions in VAS and SPADI scores at 1- and 3-month evaluations (p < 0.001). However, the TECAR group demonstrated greater improvements compared to the control group. After treatment, both groups showed a significant reduction in bicipital effusion rates, while no significant change was observed in supraspinatus tendon thickness. Adding TECAR therapy to conventional treatment offered additional benefits in reducing pain and improving function in patients with AC. TECAR therapy is a promising, non-invasive, and cost-effective treatment option for AC with relatively few sessions. CLINICAL TRIALS ID: NCT06784128, Retrospectively Registered. STUDY REGISTRATION DATE: 2025-01-15.
TECAR疗法是一种热疗方式，通过在浅表和深部组织中产生热量来增强微循环、减轻炎症并支持组织再生。本研究旨在评估TECAR疗法对粘连性肩周炎（AC）患者疼痛和功能结局的影响。这项前瞻性、随机、单盲、对照临床试验纳入了60例患者[TECAR组：30例，（50.37±13.90岁）；对照组：30例，（55.27±10.44岁）]。两组均完成了为期2周的定制治疗性锻炼计划，包括30分钟的热敷和经皮电刺激神经疗法。TECAR组还每周接受3次TECAR疗法治疗，共6次。使用视觉模拟量表（VAS）测量疼痛，用肩痛和功能障碍指数（SPADI）评估功能状态，并通过超声检查评估冈上肌腱厚度和肱二头肌积液情况。在基线、治疗后1个月和3个月进行评估。两组在治疗后1个月和3个月的评估中VAS和SPADI评分均显著降低（p<0.001）。然而，与对照组相比，TECAR组的改善更为明显。治疗后，两组肱二头肌积液率均显著降低，而冈上肌腱厚度未观察到显著变化。在常规治疗中添加TECAR疗法在减轻AC患者疼痛和改善功能方面提供了额外的益处。TECAR疗法是一种有前景的、非侵入性且经济高效的治疗AC的方法，所需治疗次数相对较少。临床试验识别号：NCT06784128，回顾性注册。研究注册日期：2025年1月15日。
